Navigation Links
Cell Therapeutics, Inc. Announces Institutional Investors Purchase Approximately $16.0 Million of Preferred Stock and Warrants
Date:4/27/2011

SEATTLE, April 28, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell, subject to customary closing conditions, approximately $16.0 million of shares of its Series 12 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to three institutional investors.  Each share of Series 12 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 2,857 shares of common stock at a conversion price of $0.35 per share of common stock, for a total of 45,634,286 shares of common stock.

In connection with the offering, the investors received warrants to purchase up to 18,253,714 shares of common stock.  The warrants have an exercise price of $0.40 per warrant share, for total potential additional proceeds to the Company of approximately $7.3 million upon exercise of the warrants for cash. The warrants are exercisable immediately and expire five years from the date of issuance.

The Company intends to use the net proceeds from the offering for general corporate purposes, which may include, among other things, paying interest on and/or retiring portions of its outstanding debt, funding research and development, preclinical and clinical trials, the preparation and filing of new drug applications and general working capital.  The Company may also use a portion of the net proceeds to fund possible investments in, or acquisitions of, complementary businesses, technologies or products.  The Company has recently engaged in limited discussions with third parties regarding such investments or acquisitions, but has no current agreements or commitments with respect to any investment or acquisition.

Shares of the Series 12 Preferred Stock will receive dividends in the same amount as any dividends declared and paid on shares of common stock and have no voting ri
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014 Northstar Global Business ... after months of hard work from many talented ... Snorenz formulation and package design.  The new formulation ... back into the product due to overwhelming evidence ... effects.  Snorenz Nighttime will also include these vitamins, ...
(Date:8/20/2014)... 2014  The National Association of Drug Diversion ... by the real-time, pseudoephedrine (PSE) blocking system in ... Exchange (NPLEx), automatically blocks unlawful PSE sales and ... and make arrests. Data released by NPLEx shows ... blocked the sale of more than 32,105 boxes of ...
(Date:8/20/2014)... , Aug. 20, 2014  The National Association ... latest results achieved by the real-time, pseudoephedrine (PSE) ... National Precursor Log Exchange (NPLEx), automatically blocks unlawful ... down meth offenders and make arrests. Data released ... Kentucky blocked the sale of more ...
Breaking Medicine Technology:Northstar completes the first phase of its new retail strategy and prepares to ship reformulated Snorenz with all new packaging 2Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2Kentucky's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... LOS ANGELES & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 17, ... focused on,the discovery and development of novel, ... of AV-412, a novel,next generation oral tyrosine ... mutant and drug-resistant lung cancer tumor,models. The ...
... Decreased Tumor Blood Vessel,Density and Serum PSA ... and TUSTIN, Calif., April 17, 2007,/PRNewswire-FirstCall/ -- ... company developing targeted,monoclonal antibodies for the treatment ... today announced that preclinical data,presented at the ...
Cached Medicine Technology:AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 2AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 3AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 4Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 2Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 3Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 4Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 5
(Date:8/21/2014)... CA (PRWEB) August 21, 2014 AttorneyOne.com, ... regarding all the latest information from the FDA on ... , The US FDA announced on August 15, that ... Solution with 2.5% Dextrose 5000mL (Ambu-Flex II), by Baxter ... presence of particulate matter. , The reason for ...
(Date:8/21/2014)... 21, 2014 Inc. magazine ranked Centurion ... 500|5000, an exclusive ranking of the nation's fastest-growing private ... the most important segment of the economy—America’s independent entrepreneurs. ... LinkedIn, Zillow, and many other well-known names gained early ... is proud to have been named to the Inc. ...
(Date:8/21/2014)... Washington Crossing, PA (PRWEB) August 21, 2014 ... at Washington Crossing Historic Park in Washington Crossing, Pennsylvania ... to maintain the park. “We have been looking for ... community organizations,” said Matt Kiernan, Partner with Pharmica Consulting. ... a significant part of U.S. history, we jumped at ...
(Date:8/21/2014)... 2014 The Rottenstein Law Group LLP, ... years of experience advocating for plaintiffs with claims of ... devices, announces the launch of its new website, ... believe they have been harmed by prescription drugs or ... the severe adverse side effects suffered by women allegedly ...
(Date:8/21/2014)... She was 12 years old when the unthinkable happened ... to correct her frequent headaches failed. , In her ... shares her journey of overcoming devastating obstacles involving dual disability, ... of justice for years. , “My faith in God ... the light,” Strom-Stewart said. “But it took me more than ...
Breaking Medicine News(10 mins):Health News:Dianeal Low Calcium (2.5mEq/L) Peritoneal Dialysis Solution with 2.5% Dextrose 5000mL (Ambu-Flex II) Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 2Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 3Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 4Health News:Pharmica Spends the Day Helping to Preserve Washington Crossing Historic Park 2Health News:Rottenstein Law Group LLP Announces Launch of WeHelpWomen.com 2Health News:The Dramatic, Uplifting Story from a Brain Injured Woman 2
... at Online Radiology Medical Group, Inc. is pleased to announce new ... and functional MRI consulting and reading services. , ... ... -- Jesse Salen, the VP of Sales and Technology at ...
... metabolism booster, weight reducer and athletic enhancer, sales of acai products have ... in the Brazilian rainforest from acai palms that may reach heights in ... harvest edible hearts of palm. , ... Green Bay, WI (PRWEB) November ...
... which young people livefamilies, peers, schools, and neighborhoodscontribute both ... risk from one area possibly being magnified or decreased ... a new longitudinal study conducted by researchers at the ... of California at Davis, and the University of California ...
... little to other diagnostic measures, British researchers report , , ... (EKG) -- the standard test for measuring the activity ... predicting future coronary problems for people who are examined ... "In patients with stable chest pain, suspected angina, the ...
... 13, 2008 James G.,Carlson, Chairman and CEO of AMERIGROUP ... Birth Report Card," which was,released November 12 by the March ... fair chance to grow up in good,health. But as the ... Report Card, that is not the case today. Studies show ...
... There are more than 70,million Americans over the ... part,of Kmart,s effort to provide helpful information about growing ... November 18th from 9am-1pm,at all 1100 Kmart pharmacy locations., ... blood pressure,screenings, free memory screenings, Medicare health plan selection,assistance ...
Cached Medicine News:Health News:New Teleradiology Reading Services Are Available at Online Radiology Medical Group, Inc. 2Health News:New Teleradiology Reading Services Are Available at Online Radiology Medical Group, Inc. 3Health News:Research Finds The Brazilian Acai Absorbs Much Better Than Any Other Fruit 2Health News:Families, friends, schools and neighborhoods contribute to adolescent alcohol misuse 2Health News:EKG Not Strong Predictor of Heart Risk 2Health News:EKG Not Strong Predictor of Heart Risk 3Health News:AMERIGROUP Chairman and CEO Urges Action to Improve Nation's 'Premature Birth Report Card' 2Health News:Kmart Pharmacy Celebrates GoldK Day for Seniors 2
Passive heat and moisture exchangers for respiratory applications....
Ballard trach care HMES and filters, tv1000, HME...
Ballard trach care HMES and filters, tv 500, HME...
Indications For Usage:, ,Single use on tracheostomy patients who can breathe spontaneously. The product is intended to be replaced at least once every 24 hours....
Medicine Products: